Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2018 Jul;41(7):945-952.
doi: 10.1002/clc.22981. Epub 2018 Jul 17.

Rate pressure product and the components of heart rate and systolic blood pressure in hospitalized heart failure patients with preserved ejection fraction: Insights from ASCEND-HF

Amanda K Verma  1 , Jie-Lena Sun  2 , Adrian Hernandez  3 , John R Teerlink  4 , Phillip J Schulte  5 , Justin Ezekowitz  6 , Adriaan Voors  7 , Randall Starling  8 , Paul Armstrong  6 , Christopher M O'Conner  3 , Robert J Mentz  3
Affiliations
Randomized Controlled Trial

Rate pressure product and the components of heart rate and systolic blood pressure in hospitalized heart failure patients with preserved ejection fraction: Insights from ASCEND-HF

Amanda K Verma et al. Clin Cardiol. 2018 Jul.

Abstract

Background: Heart rate and systolic blood pressure (SBP) are prognostic markers in heart failure (HF) with reduced ejection fraction (HFrEF). Their combination in rate pressure product (RPP) as well as their role in heart failure with preserved ejection fraction (HFpEF) remains unclear.

Hypothesis: RPP and its components are associated with HFpEF outcomes.

Methods: We performed an analysis of Acute Study of Clinical Effectiveness of Nesiritide in Subjects With Decompensated Heart Failure (ASCEND-HF; http://www.clinicaltrials.gov NCT00475852), which studied 7141 patients with acute HF. HFpEF was defined as left ventricular ejection fraction ≥40%. Outcomes were assessed by baseline heart rate, SBP, and RPP, as well as the change of these variables using adjusted Cox models.

Results: After multivariable adjustment, in-hospital change but not baseline heart rate, SBP, and RPP were associated with 30-day mortality/HF hospitalization (hazard ratio [HR]: 1.17 per 5-bpm heart rate, HR: 1.20 per 10-mm Hg SBP, and HR: 1.02 per 100 bpm × mm Hg RPP; all P < 0.05). Baseline SBP was associated with 180-day mortality (HR: 0.88 per 10-mm Hg, P = 0.028). Though change in RPP was associated with 30-day mortality/HF hospitalization, the RPP baseline variable did not provide additional associative information with regard to outcomes when compared with assessment of baseline heart rate and SBP variables alone.

Conclusions: An increase in heart rate and SBP from baseline to discharge was associated with increased 30-day mortality/HF hospitalization in HFpEF patients with acute exacerbation. These findings suggest value in monitoring the trend of vital signs during HFpEF hospitalization.

Keywords: Blood Pressure Control and Regulation; Clinical Trials; Heart Failure.

PubMed Disclaimer

Conflict of interest statement

Robert J. Mentz receives research support from Amgen, AstraZeneca, Bristol‐Myers Squibb, GlaxoSmithKline, Gilead, Novartis, Otsuka, and ResMed; and has received honoraria from HeartWare, Janssen, Luitpold Pharmaceuticals, Inc., Novartis, ResMed, and Thoratec/St. Jude. He has served on an advisory board for Luitpold Pharmaceuticals, Inc. The authors declare no other potential conflicts of interest.

Figures

Figure 1
Figure 1
Kaplan–Meier event curve for 180‐day all‐cause mortality in HFpEF patients by baseline SBP, with number at risk at 30‐day intervals from randomization by SBP. Abbreviations: HFpEF, heart failure with preserved ejection fraction; SBP, systolic blood pressure
See this image and copyright information in PMC

References

    1. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association [published corrections appear in Circulation 2015;131:e535 and Circulation 2016;133:e417]. Circulation. 2015;131:e29–e322. - PubMed
    1. Abbate A, Arena R, Abouzaki N, et al. Heart failure with preserved ejection fraction: rtefocusing on diastole. Int J Cardiol. 2015;179C:430–440. - PubMed
    1. Cheng RK, Cox M, Neely ML, et al. Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. Am Heart J. 2014;168:721–730. - PubMed
    1. Kitzman DW, Upadhya B, Vasu S. What the dead can teach the living: the systemic nature of heart failure with preserved ejection fraction. Circulation. 2015;131:522–524. - PMC - PubMed
    1. Greene SJ, Vaduganathan M, Wilcox JE, et al; EVEREST Trial Investigators . The prognostic significance of heart rate in patients hospitalized for heart failure with reduced ejection fraction in sinus rhythm: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan) trial. JACC Heart Fail. 2013;1:488–496. - PubMed

Publication types

MeSH terms

Substances

Associated data